165 related articles for article (PubMed ID: 38457511)
21. Insight into the Therapeutic Selectivity of the Irreversible EGFR Tyrosine Kinase Inhibitor Osimertinib through Enzyme Kinetic Studies.
Zhai X; Ward RA; Doig P; Argyrou A
Biochemistry; 2020 Apr; 59(14):1428-1441. PubMed ID: 32207968
[TBL] [Abstract][Full Text] [Related]
22. Emergence of novel and dominant acquired EGFR solvent-front mutations at Gly796 (G796S/R) together with C797S/R and L792F/H mutations in one EGFR (L858R/T790M) NSCLC patient who progressed on osimertinib.
Ou SI; Cui J; Schrock AB; Goldberg ME; Zhu VW; Albacker L; Stephens PJ; Miller VA; Ali SM
Lung Cancer; 2017 Jun; 108():228-231. PubMed ID: 28625641
[TBL] [Abstract][Full Text] [Related]
23. Patients with uncommon EGFR mutations also benefit from first-line osimertinib.
Romero D
Nat Rev Clin Oncol; 2024 Feb; 21(2):84. PubMed ID: 38057403
[No Abstract] [Full Text] [Related]
24. Osimertinib-related liver injury with successful osimertinib rechallenge: A case report.
Cheng YL; Chang WK; Yen H; Peng YJ; Chang WC; Chang PY
Thorac Cancer; 2022 Aug; 13(15):2271-2274. PubMed ID: 35793806
[TBL] [Abstract][Full Text] [Related]
25. Let-7c regulated epithelial-mesenchymal transition leads to osimertinib resistance in NSCLC cells with EGFR T790M mutations.
Li XF; Shen WZ; Jin X; Ren P; Zhang J
Sci Rep; 2020 Jul; 10(1):11236. PubMed ID: 32641854
[TBL] [Abstract][Full Text] [Related]
26. Osimertinib in Patients With Non-Small Cell Lung Cancer and Uncommon EGFR Mutations-Chasing Unicorns?
Wang VE; Gainor JF
JAMA Oncol; 2024 Jan; 10(1):52-53. PubMed ID: 37991771
[No Abstract] [Full Text] [Related]
27. Lazarus effect in a patient initially empirically treated with osimertinib for
Bhatia S; Cortez MG; Lessans S; Iams WT
Oncotarget; 2024 Jan; 15():27-30. PubMed ID: 38227738
[TBL] [Abstract][Full Text] [Related]
28. Efficacy of osimertinib in patients with EGFR-mutation positive non-small cell lung cancer with malignant pleural effusion.
Kiritani A; Amino Y; Uchibori K; Akita T; Harutani Y; Ogusu S; Tsugitomi R; Manabe R; Ariyasu R; Kitazono S; Yanagitani N; Nishio M
Thorac Cancer; 2024 Feb; 15(5):402-409. PubMed ID: 38226415
[TBL] [Abstract][Full Text] [Related]
29. ID1 mediates resistance to osimertinib in EGFR T790M-positive non-small cell lung cancer through epithelial-mesenchymal transition.
Liu K; Chen X; Wu L; Chen S; Fang N; Cai L; Jia J
BMC Pulm Med; 2021 May; 21(1):163. PubMed ID: 33992097
[TBL] [Abstract][Full Text] [Related]
30. Base-Controlled Palladium-Catalyzed Intramolecular 'One Substrate - Five Reactions' of 5-Benzyl-1-(2-halobenzyl)-2-phenyl-1H-pyrazol-3(2H)-ones.
Liu C; Zhu X; Liu Y; Yang H; Fu H
Chemistry; 2023 Apr; 29(19):e202203974. PubMed ID: 36653308
[TBL] [Abstract][Full Text] [Related]
31. Development and Optimization of Osimertinib-loaded Biodegradable Polymeric Nanoparticles Enhance In-vitro Cytotoxicity in Mutant EGFR NSCLC Cell Models and In-vivo Tumor Reduction in H1975 Xenograft Mice Models.
K SK; Choppala AD
AAPS PharmSciTech; 2022 Jun; 23(5):159. PubMed ID: 35676448
[TBL] [Abstract][Full Text] [Related]
32. Osimertinib Plus Bevacizumab Versus Osimertinib for Untreated Nonsquamous NSCLC Harboring EGFR Mutations.
Zhao B; Xing H; Ma W
J Thorac Oncol; 2022 Sep; 17(9):e76-e77. PubMed ID: 36031292
[No Abstract] [Full Text] [Related]
33. One-pot synthesis of pyrimido[1,6-a]indol-1(2H)-one derivatives by a nucleophilic addition/Cu-catalyzed N-arylation/Pd-catalyzed C-H activation sequential process.
Wang ZJ; Yang JG; Yang F; Bao W
Org Lett; 2010 Jul; 12(13):3034-7. PubMed ID: 20527777
[TBL] [Abstract][Full Text] [Related]
34. Rapid Access to Kinase Inhibitor Pharmacophores by Regioselective C-H Arylation of Thieno[2,3-
Yamada S; Flesch KN; Murakami K; Itami K
Org Lett; 2020 Feb; 22(4):1547-1551. PubMed ID: 32009412
[TBL] [Abstract][Full Text] [Related]
35. Activation of insulin-like growth factor-1 receptor confers acquired resistance to osimertinib in non-small cell lung cancer with EGFR T790M mutation.
Hayakawa D; Takahashi F; Mitsuishi Y; Tajima K; Hidayat M; Winardi W; Ihara H; Kanamori K; Matsumoto N; Asao T; Ko R; Shukuya T; Takamochi K; Hayashi T; Suehara Y; Takeda Nakamura I; Ueno T; Kohsaka S; Mano H; Takahashi K
Thorac Cancer; 2020 Jan; 11(1):140-149. PubMed ID: 31758670
[TBL] [Abstract][Full Text] [Related]
36. Design, synthesis and evaluation of the osimertinib analogue (C-005) as potent EGFR inhibitor against NSCLC.
Zhou P; Chen G; Gao M; Wu J
Bioorg Med Chem; 2018 Dec; 26(23-24):6135-6145. PubMed ID: 30442506
[TBL] [Abstract][Full Text] [Related]
37. Xenograft tumors derived from malignant pleural effusion of the patients with non-small-cell lung cancer as models to explore drug resistance.
Xu Y; Zhang F; Pan X; Wang G; Zhu L; Zhang J; Wen D; Lu S
Cancer Commun (Lond); 2018 May; 38(1):19. PubMed ID: 29764505
[TBL] [Abstract][Full Text] [Related]
38. Chemotherapy and Osimertinib Combination Should Not Be the First-Line Treatment for All Advanced EGFR+ NSCLC.
Lim SM; Lee JB; Cho BC
J Thorac Oncol; 2024 Mar; 19(3):376-379. PubMed ID: 38453325
[No Abstract] [Full Text] [Related]
39. Chemotherapy and Osimertinib Combination Should Be the First-Line Treatment for All Advanced EGFR+ NSCLC.
Chen LN; Lee ATM; Nagasaka M; Ou SI
J Thorac Oncol; 2024 Mar; 19(3):380-384. PubMed ID: 38453326
[No Abstract] [Full Text] [Related]
40. From α-arylation of olefins to acylation with aldehydes: a journey in regiocontrol of the Heck reaction.
Ruan J; Xiao J
Acc Chem Res; 2011 Aug; 44(8):614-26. PubMed ID: 21612205
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
